Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 23

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

384

HTML

2766

Figures (1-2)

161

Tables (1-3)

166

Sum=3477

Jun 21, 2007 (publication date) through Oct 2, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Jun 21, 2007; 13(23): 3232-3236
Published online Jun 21, 2007. doi: 10.3748/wjg.v13.i23.3232

Table 2 Stages according to the METAVIR criteria (Bedossa et al)

Stage 0	No fibrosis
Stage 1	Mild fibrosis (portal/periportal fibrosis, no septa)
Stage 2	Moderate fibrosis (few septa)
Stage 3	Severe fibrosis (many septa, no cirrosis)
Stage 4	Cirrhosis

Citation: Larsen FS, Vainer B, Eefsen M, Bjerring PN, Hansen BA. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13(23): 3232-3236
URL: https://www.wjgnet.com/1007-9327/full/v13/i23/3232.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i23.3232